for people ages 4-55 (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Dorsey, Morna



The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through characterized oral desensitization immunotherapy (CODIT) in peanut-allergic children and adults who have completed the ARC003 study.

Official Title

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study


This is an international, multicenter, open-label, 2-arm follow-on study of the safety, tolerability, and efficacy of AR101 in peanut-allergic individuals who have completed the ARC003 study. This study will explore alternative dosing regimens during extended maintenance with AR101.


Peanut Allergy AR101 Characterized Peanut Allergen CPNA (Characterized Peanut Allergen) OIT (oral immunotherapy) Allergy Peanut-Allergic Children Peanut-Allergic Adults Desensitization PALISADE Hypersensitivity Peanut Hypersensitivity


You can join if…

Open to people ages 4-55

  • Completion of the ARC003 study
  • Written informed consent and/or assent from subjects/guardians as appropriate
  • Use of effective birth control by sexually active female subjects of child-bearing potential

You CAN'T join if...

  • Early discontinuation from the ARC003 study
  • Meets any longitudinally applicable ARC003 study exclusion criteria
  • (Group 2 only) Failure to tolerate ≥ 443 mg cumulative of peanut protein with no or mild symptoms in the ARC003 study Exit DBPCFC
  • Any other condition that, in the opinion of the Investigator, precludes participation for reasons of safety


  • University of California, San Francisco
    San Francisco California 94158 United States
  • Sean N. Parker Center for Allergy Research at Stanford University Packard-El Camino Hospital
    Mountain View California 94040 United States

Lead Scientist

  • Dorsey, Morna
    1. Optimizing diagnosis and care of patients with primary immunodeficiency 2. Investigating the psychosocial impact of primary immunodeficiency on patients and families 3. Establishing treatment for patients with food allergy and eosinophilic disorders


in progress, not accepting new patients
Start Date
Completion Date
Aimmune Therapeutics, Inc.
Click to request more information about this study.
Phase 3
Study Type
Last Updated